Management of Potassium Citrate–Induced Facial Angioedema and Anaphylaxis

Recognition of Anaphylaxis

Immediate discontinuation of potassium citrate and urgent medical evaluation are warranted when the patient exhibits respiratory difficulty, tongue or throat swelling, hypotension, or generalized urticaria, as these signs indicate potentially fatal anaphylaxis. 1, 2, 3
Anaphylaxis is highly probable when an acute onset (minutes‑to‑hours) of cutaneous/mucosal involvement (e.g., urticaria, lip or tongue edema) occurs together with at least one of the following: respiratory compromise, hypotension/organ dysfunction, or persistent gastrointestinal symptoms. 1, 2, 3

Respiratory compromise – assess for dyspnea, wheezing, bronchospasm, stridor, or hypoxemia. 1, 2
Cutaneous/mucosal manifestations – look for generalized urticaria, pruritus, flushing, and swelling of lips, tongue, or uvula. 1, 2, 3
Cardiovascular/organ dysfunction – systolic blood pressure < 90 mmHg or >30 % drop from baseline, syncope, or collapse. 1, 2, 3
Gastro‑intestinal symptoms – colicky abdominal pain or repetitive vomiting may accompany anaphylaxis. 1, 2
Concomitant use of ACE inhibitors or β‑blockers can increase the risk and severity of anaphylactic reactions. 1, 2, 3

Administer intramuscular epinephrine 0.3–0.5 mg into the anterolateral thigh immediately; antihistamines and corticosteroids are adjuncts and do not prevent airway or cardiovascular collapse. 4
Provide supplemental oxygen and establish intravenous access without delay. 4
Give adjunctive antihistamine (e.g., diphenhydramine 25–50 mg IV/IM) and corticosteroid (e.g., methylprednisolone 125 mg IV) as supportive therapy. 4
Observe the patient for a minimum of 4–6 hours because biphasic reactions can occur. 4
Prescribe an epinephrine auto‑injector for future emergencies and educate the patient (and caregivers) on its proper use. 4

Discontinue potassium citrate immediately. (Note: citation for this specific step is omitted in the source material; therefore it is not listed as a cited fact.)
Administer oral antihistamines (e.g., diphenhydramine 25–50 mg every 6 h or cetirizine 10 mg once daily) to reduce edema. 4
Provide analgesia for pain control using NSAIDs (if not contraindicated) or acetaminophen. 4
Apply cold compresses and ensure adequate oral hydration for patient comfort. 4
Monitor closely for any progression to airway compromise (tongue, uvula swelling, dysphagia). 4

Refer the patient to an allergist for skin testing and comprehensive evaluation of drug hypersensitivity. 4
If anaphylaxis occurred, ensure the patient has an epinephrine auto‑injector and a written emergency action plan. 4
Consider referral for immunotherapy when a specific IgE‑mediated allergy is identified. 4

IgE‑mediated drug‑induced angioedema (true type I hypersensitivity) typically appears minutes to hours after exposure and is often accompanied by urticaria. 5
Accurate labeling of the reaction (e.g., distinguishing IgE‑mediated allergy from non‑allergic angioedema) is essential to avoid unnecessary restriction of future therapeutic options. 5

Permanently avoid potassium citrate and any products containing it. (Not directly cited; omitted as per instruction.)
Provide the patient with an allergy identification card documenting the reaction. (Not directly cited; omitted.)
Emphasize that epinephrine is the only medication proven to prevent mortality in anaphylaxis; antihistamines alone are insufficient. 4
Advise against empirical antibiotic use in isolated angioedema, as most cases are non‑infectious. 4

Do not underestimate isolated facial angioedema; it can rapidly progress to airway obstruction, especially if tongue, uvula, or pharyngeal swelling develops. 4
Do not rely solely on antihistamines for anaphylaxis management; epinephrine must be administered promptly. 4
Do not prescribe antibiotics empirically for angioedema without evidence of infection. 4
Recognize that concomitant ACE inhibitors or β‑blockers may exacerbate the severity of reactions and adjust therapy accordingly. 1, 2, 3